Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma
Open Access
- 24 December 2013
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 110 (3) , 616-624
Abstract
Background: Methods: Results: Conclusion:Keywords
This publication has 39 references indexed in Scilit:
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- Effectiveness of semi-quantitative multiphase dynamic contrast-enhanced MRI as a predictor of malignancy in complex adnexal masses: radiological and pathological correlationEuropean Radiology, 2011
- Assessment of Response to Tyrosine Kinase Inhibitors in Metastatic Renal Cell Cancer: CT Texture as a Predictive BiomarkerRadiology, 2011
- Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot studyCancer Imaging, 2011
- Pretreatment assessment of tumor enhancement on contrast‐enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapyCancer, 2010
- Computed Tomography in Metastatic Renal Cell CarcinomaSeminars in Ultrasound, CT and MRI, 2009
- Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancerGynecologic Oncology, 2008
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacodynamic Biomarker Study of Sorafenib in Metastatic Renal CarcinomaJournal of Clinical Oncology, 2008
- Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinomaCancer Biology & Therapy, 2008
- Diffusion Magnetic Resonance Imaging: A Biomarker for Treatment Response in OncologyJournal of Clinical Oncology, 2007